PAIT-Survey Follow-Up: Changes in Albuminuria in Hypertensive Diabetic Patients with Mild-Moderate Chronic Kidney Disease

Fıcı, Francesco; Bakır, Elif Arı; Yüce, Elif İlkay; Kanuncu, Serdal; Makel, Wim; Tarim, Bahar Arican; Robles, Nicolás Roberto

doi:10.1007/s40292-020-00358-1

Cited by 5 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The RED LEVEL study by Robles et al [ 154 ], which compared combination therapy of enalapril plus lercanidipine with enalapril plus amlodipine, found that, while there was no significant difference in BP control between the two groups, the lercanidipine plus enalapril combination had a superior anti-albuminuric effect. Similar results were shown in a study by Fici et al [ 155 ], which found that, among treatments with different combinations of RAAS blockers and CCBs, multitherapy of lercanidipine with enalapril had the highest rate of albuminuria reduction. This evidence might favor the administration of lercanidipine combined with RAAS inhibitors to control BP and the albuminuria rate in diabetic patients with hypertension [ 154 , 155 ].…”

Section: Lercanidipine As Hypertensive Medicament and Its Comparison ...supporting

confidence: 90%

“…Similar results were shown in a study by Fici et al [ 155 ], which found that, among treatments with different combinations of RAAS blockers and CCBs, multitherapy of lercanidipine with enalapril had the highest rate of albuminuria reduction. This evidence might favor the administration of lercanidipine combined with RAAS inhibitors to control BP and the albuminuria rate in diabetic patients with hypertension [ 154 , 155 ]. From all of the studies mentioned above, the ones most significant to our research are summarized in Table 4 .…”

Section: Lercanidipine As Hypertensive Medicament and Its Comparison ...supporting

confidence: 90%

See 1 more Smart Citation

New Insights into the Nephroprotective Potential of Lercanidipine

Hajdys,

Fularski,

Leszto

et al. 2023

IJMS

View full text Add to dashboard Cite

Kidneys are responsible for many crucial biological processes in the human body, including maintaining the water–electrolyte balance, pH, and blood pressure (BP), along with the elimination of toxins. Despite this, chronic kidney disease (CKD), which affects more and more people, is a disease that develops insidiously without causing any symptoms at first. The main purpose of this article is to summarize the existing literature on lercanidipine, with a particular focus on its nephroprotective properties. Lercanidipine is a third-generation dihydropyridine (DHP) blocker of calcium channels, and as such it possesses unique qualities such as high lipophilicity and high vascular selectivity. Furthermore, it acts by reversibly inhibiting L-type and T-type calcium channels responsible for exerting positive renal effects. It has been shown to reduce tissue inflammation and tubulointerstitial fibrosis, contributing to a decrease in proteinuria. Moreover, it exhibited antioxidative effects and increased expression of molecules responsible for repairing damaged tissues. It also decreased cell proliferation, preventing thickening of the vascular lumen. This article summarizes studies simultaneously comparing the effect of lercanidipine with other antihypertensive drugs. There is still a lack of studies on the medications used in patients with CKD, and an even greater lack of studies on those used in patients with concomitant hypertension. Therefore, further studies on lercanidipine and its potential in hypertensive patients with coexisting CKD are required.

show abstract

Section: Lercanidipine As Hypertensive Medicament and Its Comparison ...supporting

confidence: 90%

Section: Lercanidipine As Hypertensive Medicament and Its Comparison ...supporting

confidence: 90%

New Insights into the Nephroprotective Potential of Lercanidipine

Hajdys,

Fularski,

Leszto

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Globally proteinuria was decreased by 33-37% with the combination Lercanidipine/Enalapril RAAS blocking drugs 50 . The PAIT-Survey Follow-Up 51 , performed in patients with hypertension, diabetes and proteinuria has shown that the prevalence of subjects with microalbuminuria was significantly (p<0.01) decreased after 6 months of Lercanidipine/Enalapril treatment. Particularly this effect has been much greater with Lercanidipine/Enalapril (-41.3%) compared with amlodipine-valsartan (-15.6%), amlodipineperindopril (-11.8%) and verapamil-trandolapril, (-19.2%).…”

Section: What Is the Evidence Of Lercanidipine/enalapril On Renal Pro...mentioning

confidence: 99%